Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the ...
China’s National Medical Products Administration (NMPA) has granted regulatory approval for 2 next-generation ophthalmic ...
NImmune Biopharma ("NImmune"), a private late-stage precision inflammation and immunology ("I&I") biopharmaceutical company, today announced that Executive Chairman, President and CEO Dr. Josep ...
The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...
New research shows that 30-second bursts of intense cardio can reduce panic symptoms by teaching your nervous system that ...
Disc Medicine stock is hit by an FDA CRL for bitopertin. Learn key trial risks, cash runway, and why APOLLO Phase 3 results ...
Israel’s Teva Pharmaceutical Industries US unit and French pharma major Sanofi today announced positive results from the RELIEVE UCCD long-term extension (LTE) study of duvakitug, an investigational ...
Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished ...
Early findings from the ongoing MIRACLE clinical trial suggest that the investigational drug annamycin, given with cytarabine, may help more patients with relapsed or refractory acute myeloid leukemia ...
NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global ...
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results